 SEATTLE, May 12, 2022 GLOBE NEWSWIRE -- Impel Pharmaceuticals Inc. NASDAQ: IMPL, a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 5:00 p.m. ET in Miami, Florida. 